← Back to Search

Hormone Therapy

Adjuvant for Prostate Cancer

Phase 2
Waitlist Available
Led By Tamim Niazi, MD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trialevaluates a drug and radiation therapy combo to help prostate cancer patients after surgery. It looks at the success rate 5 years later.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AdjuvantExperimental Treatment1 Intervention
Adjuvant suppression plus radiation therapy

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
408 Previous Clinical Trials
1,018,362 Total Patients Enrolled
Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
58 Previous Clinical Trials
21,170 Total Patients Enrolled
17 Trials studying Prostate Cancer
3,699 Patients Enrolled for Prostate Cancer
AbbottIndustry Sponsor
753 Previous Clinical Trials
479,189 Total Patients Enrolled
7 Trials studying Prostate Cancer
2,619 Patients Enrolled for Prostate Cancer
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top